There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Acelrx (ACRX) and Sensus Healthcare Inc (SRTS) with bullish sentiments.
In a report issued on March 8, David Buck from B.Riley FBR reiterated a Buy rating on Acelrx, with a price target of $7.50. The company’s shares opened today at $3.18.
“We reiterate our Buy rating for AcelRx (ACRX) following 4Q18 results, which reflected results prior to the key U.S. DSUVIA launch for acute pain in a medically supervised setting. Non-GAAP EPS (loss) of ($0.16) topped our ($0.21) forecast and GAAP results of ($0.18) topped ($0.20) consensus. For 2019, AcelRx did not provide any revenue guidance as expected; however, metrics on the early (product shipped in February 2019 to wholesalers) offered encouragement. First, AcelRx is now targeting 125 formulary wins by end of 2019 versus a goal of 100 previously. Sales force expansion to 40 hospital account managers (from 15 currently and at initial launch) moves up to 3Q19 from original 4Q19 target and the company continues to target full strength at 60 hospital account managers by 1Q20.”
According to TipRanks.com, Buck has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.4% and a 37.7% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.
Currently, the analyst consensus on Acelrx is a Strong Buy with an average price target of $8.40, a 164.2% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $9 price target.
See today’s analyst top recommended stocks >>
Sensus Healthcare Inc (SRTS)
In a report released today, Andrew D’silva from B.Riley FBR reiterated a Buy rating on Sensus Healthcare Inc, with a price target of $14. The company’s shares opened today at $7.63.
“We are adding Sensus Healthcare (SRTS) to our Alpha Generator list. We think the company’s SRT-100 family of systems should continue to see improving adoption metrics as it progresses along the “S-curve.” We believe a best-in-class technology, favorable industry backdrop, positive data, and substantial momentum, indicate that the company is reaching an inflection point, which should result in strong growth and share price appreciation. Furthermore, we think that new technologies that improve patient outcomes and are differentiated from other treatment options are well positioned to be adopted at a rapid clip. For example, the majority of applicable centers began utilizing both intensity-modulated radiation therapy and image-guided radiation therapy within 10 years of early adopters.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 9.2% and a 43.6% success rate. D’silva covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Imprimis Pharmaceuticals, and Oramed Pharmaceuticals.
Currently, the analyst consensus on Sensus Healthcare Inc is a Moderate Buy with an average price target of $11.50, representing a 50.7% upside. In a report issued on February 27, H.C. Wainwright also reiterated a Buy rating on the stock with a $13 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.